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Research Updates

Research highlights
Ruta Graveolens Reducing Cell Viability in
Breast Cancer Cells
Title: In vitro antitumor activity in breast cancer cells (SKBR3
and PMC42) of Ruta graveolens in homoeopathic dilution.
Authors: Ana Catarina Viana Valle, Aloísio Cunha De
Carvalho, Hilana Dos Santos Sena Brunel, Maria Tereza de
Oliveira Rodrigues, Rosângela Vieira De Andrade.
Journal: Journal of integrated standardised homoeopathy,
DOI: 10.25259/JISH_31_2022
Summary: In the present study, the evaluation of in vitro effects
of different dilutions of Ruta D35 for treating two breast cancer
lines (SKBR3 and PMC42) has been done. Ruta D35 had
significantly reduced cell viability in the SKBR3 line compared
to the control of untreated cells. A significant difference was
obtained from the concentration of 8 μl/ml (P = 0.0391*). The
dose response effect was more evident in SKBR3 cells treated
with higher Ruta D35 concentrations (50 μL/mL). Conversely,
Ruta D35 significantly reduced cell viability in the PMC42 line
at higher concentrations (20–50 μL/mL).
Comments: Ruta graveolens D35 had significantly reduced
cell viability in the SKBR3 line compared to the control of
untreated cells. Cellular damage was observed in the SKBR3
line, leading to a significant reduction in cell viability at low
concentrations (8 μL/mL). In contrast, no significant reduction
in cell viability was recorded in the PMC42 line when exposed
to the same concentration. Ultradiluted Ruta graveolens have
the antitumor capacity, but further tests are necessary to better
understand the cytotoxic action and the potential of Ruta
graveolens for treating breast tumour cells.

Avena sativa and Echinacea angustifolia for
Haematological Parameters of Magellanic
Penguins during the Reproductive Period

and Avena sativa 6cH (N = 8; four breeding couples) and a
placebo control group (N = 10; five breeding couples). The
verum group was treated with Echinacea angustifolia 6cH and
Avena sativa 6cH in sucrose globules administered orally in the
fish that were fed to each penguin. The control group received
globules (placebos) consisting of the same inert vehicle but
without the homoeopathic preparation. Two blood collections
were performed: The first collection was done before the
beginning of the reproductive period and the administration
of the treatments, and the second collection was done after the
second egg of each couple had been laid. Mean corpuscular
volume (MCV), in the verum group, showed an increase
(29.78 ± 52.95 fL) while the control group showed stability/
reduction (−3.08 ± 46.36 fL) (P = 0.049). Proportion of
heterophils, in the verum group, showed a less marked increase
(8.38±12.53%) than that of the control group (18.00 ± 9.37%)
(P = 0.010). Lymphocyte concentration, in the verum group,
showed less marked reduction (−4.39 ± 2.21 × 109 cells/L)
than that of the control group (−1.56 ± 2.76 × 109 cells/L)
(P = 0.001). Proportion of lymphocytes, in the verum group,
showed a less marked reduction (−6.75 ± 10.35%) than that
of the control group (−17.3 ± 8.73%) (P = 0.002).
Comments: Comparison of samples collected before
and during the reproductive period showed that there
were differences in the effects on MCV, heterophils and
lymphocytes. Treatment with Echinacea angustifolia and
Avena sativa resulted in the maintenance of lymphocyte levels
in Magellanic penguins during the breeding period, thus aiding
these birds’ immunity.

Role of Homoeopathy in Irritable Bowel
Syndrome
Title: Efficacy of individualised homoeopathic medicines
in irritable bowel syndrome: A double-blind, randomised,
placebo-controlled trial

Title: Evaluation of the Effects of Administering Ultradiluted
Avena sativa and Echinacea angustifolia on the Haematological
Parameters of Magellanic penguins (Spheniscus magellanicus)
during the Reproductive Period.

Authors: Aakash Deep Das, Shubhamoy Ghosh, Chithra
Palanisamy, Nilanjana Guha, Sanjukta Mandal, Shukdeb
Maiti, Arunava Nath, Navin Kumar Singh, Munmun Koley,
Subhranil Saha.

Authors: Franscinne Brait Narita, Melina Castilho de Souza
Balbueno, Michele Legnaro Yang Kleber da Cunha Peixoto
Jr, Ralph E.T. Vanstreels Cidéli de Paula Coelho

Journal: Explore. https://doi.org/10.1016/j.explore.2022.10.004

Journal: Hoomeopathy. DOI: 10.1055/s-0042-1751308
Summary: Penguins (N = 18), kept under human care in a
zoological park setting, were evaluated during the reproductive
period and were divided randomly into two groups: Verum
group subjected to treatment with Echinacea angustifolia 6cH
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Summary: This study was a randomised, placebo-controlled
trial which has highlighted the effect of individualised
homoeopathic medicines on patients suffering from
inflammatory bowel syndrome. Sixty patients were taken,
divided into two groups, 30 were prescribed individualised
homoeopathic medicines and 30 were prescribed placebo.
The primary outcome measures were the IBS quality of
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life (IBS-QOL) questionnaire and the secondary outcome
measures were IBS severity scoring system (IBS-SSS) and
EQ-5D-5L scores. All scales were measured at baseline
and every month up to 3 months. Group differences in IBSQOL total scores, IBS-SSS and EQ-5D-5L scores favoured
homoeopathic treatment against placebo overall and at all the
time points (all P < 0.001). Pulsatilla nigricans (n = 4, 6.7%)
and Thuja occidentalis (n = 4, 6.7%) were the most frequently
prescribed medicines.
Comments: Individualised homoeopathic medicines
act significantly in this study. The group receiving the
homoeopathic medicines showed better results than the
placebo group.

Allium sativum 6C in Correcting Dyslipidaemia in
Rat Models
Title: Evaluation of hypolipidaemic activity of homoeopathic
drug Allium sativum 6C potency on different grades of
dyslipidaemia in Wistar albino rat models
Authors: Thangarajeswari Mohana, Kalaiselvi Periandavana,
Debadatta Nayak
Journal: Phytomedicine Plus. https://doi.org/10.1016/j.
phyplu.2022.100354
Summary: This study evaluated the hypolipidaemic and antiinflammatory activities of Allium sativum 6C in mitigating
dyslipidaemic changes in different types of dyslipidaemic
rat models. Assessment of serum biochemical parameters,
evaluation of liver cytokines and immunoblot analysis of
inflammatory proteins were performed. Administration of a
homoeopathic preparation of Allium sativum 6C to different
types of dyslipidaemic rat model showed that there is
significant reduction in the levels of serum cholesterol and
serum triglyceride, reduction in the activity of serum marker
enzymes (AST, ALT, LDH and ALP) and reduction in the
levels of liver inflammatory cytokines (TNFα, IL-6 and IL1β). Further, the expression of inflammatory proteins (CRP,
P-selectin and E-selectin) downregulated in the liver of
dyslipidaemic animals on administration of Allium sativum
6C. Among the various dyslipidaemic models, the efficacy
of Allium sativum is more profound in the high cholesterol
diet (HCD) and high-fat diet (HFD)-fed animal models.
Analysing the gas chromatography–mass spectrometry (GC–
MS) data of A. sativum 6C revealed that it contains active
ingredients, namely undecane, 1-methylene 1H-Indene and
oxazolam that might be responsible for the anti-inflammatory
properties.
Comments: Allium sativum 6C was found effective in
reduction of the levels of serum cholesterol triglyceride,
marker enzymes, inflammatory proteins and inflammatory
cytokines. This medicine can be used for therapeutic purposes
in correcting metabolic dysfunction associated with the current
lifestyle.

Role of Homoeopathy in treatment of moderate
and severe cases of COVID-19
Title: Homoeopathy as an Adjuvant to Standard Care in
Moderate and Severe Cases of COVID-19: A Single-Blind,
Randomized, Placebo-Controlled Study
Authors: Harleen Kaur, Subhash Kaushik, Gurpreet Singh,
Arvind Kumar, Shweta Singh, Tania Chatterjee, Syed Ali,
Khushbu Gautam, Maneet Parewa, Naval Kumar Verm, Sushma
Bhatnagar, Suraj Pal Singh, Varun Shekhar, Anil Khurana
Journal: Homeopathy. DOI: 10.1055/s-0042-1755365
Summary: A total of150 patients were recruited and then
randomly divided into two groups to receive either individualized
homeopathic medicines or placebos, in addition to the standard
treatment of COVID-19. The primary outcome was time taken
to achieve RT-PCR-confirmed virus clearance for COVID-19.
Secondary outcomes were changes in the Clinical Ordinal
Outcomes Scale (COOS) of the World Health Organization, the
patient-reported Measure Yourself Medical Outcome Profile 2
(MYMOP2) scale, and several biochemical parameters. In total,
72 participants of the add-on homeopathy (AoH) group showed
conversion of RT-PCR status to negative, in an average time of
7.53 ± 4.76 days (mean ± SD), as compared with 11.65 ± 9.54
days in the add-on placebo (AoP) group (p = 0.001). The mean
COOS score decreased from 4.26 ± 0.44 to 3.64 ± 1.50 and from
4.3 ± 0.46 to 4.07 ± 1.8 in the AoH and AoP groups respectively
(p = 0.130). The mortality rate for the AoH group was 9.7%
compared with 17.3% in the AoP group. The MYMOP2 scores
between the two groups differed significantly (p = 0.001), in favor
of AoH. Inter-group differences in the pre- and post- mean values
of C-reactive protein, fibrinogen, total leukocyte count, platelet
count and alkaline phosphatase were each found to be statistically
significant (p <0.05), favoring AoH; six other biochemical
parameters showed no statistically significant differences.
Comments: The study suggests homeopathy may be an effective
adjunct to standard care for treating moderate and severe COVID-19
patients. More rigorous, including double-blinded, studies should
be performed to confirm or refute these initial findings.

Arsenicum Album 30 C for Covid-19Retrospective Analysis from Mass-level Data
Title: Homoeopathic Medicine Arsenicum album 30 C for
COVID-19 in 2020: A Retrospective Analysis from Masslevel Data.
Authors: Anupriya Chaudhary, Debadatta Nayak, Swati
Pandey, Resmy R, Anil Khurana, Covid- Study Group
Journal: Alternative Therapies in Health and Medicine.
DOI: http://alternative-therapies.com/oa/index.html?fid=7132
Summary: Data from 50 colleges from February to August
2020 showed that 10.6 million people in 13 states of India
received prophylactic medicine during the study period.
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The data of 584,980 individuals who met the study criteria
were included in the retrospective analysis. The incidence
of COVID-19 in the population cohort was 13.58/10,000
person-weeks (95% CI, 13.04–14.14), which remained nearconstant over time despite the increasing disease burden in
the country (12.87–14.52/10,000 person-weeks). Comparable
incidence rates (IRs) were observed in the study population
during the periods of lockdown (April–May 2020; IR =
13.41/10,000 person-weeks; 95% CI, 12.73–14.1) and unlock
(June–August 2020; IR = 13.84/10,000 person-weeks; 95%
CI, 12.9–14.84).

Open-label Study of Arsenicum Album 30 C
in the Prevention of COVID-19 in Individuals
Residing in Containment Areas
Title: Efficacy of Arsenicum album 30C in the Prevention of
COVID-19 in Individuals Residing in Containment areas – A
Prospective, Multicentre, Cluster-Randomised, Parallel-arm,
Community-based, Open-label Study.
Authors: Debadatta Nayak, Karthikeyan Devarajan, Partha
Pratim Pal, Hima Bindu Ponnam, Nidhi Jain, Vipul Shastri,
Ramesh Bawaskar, Raveendar Chinta, Anil Khurana
Journal: Complement Med Res. DOI: 10.1159/000526897
Summary: This study was a prospective, multicentre, clusterrandomised, parallel-arm, community-based, open-label study
involving apparently healthy individuals residing in containment
areas of seven cities of India. This study was undertaken to
evaluate the protective efficacy and safety of the Arsenicum
album 30C. The analysis included 32,186 individuals residing
in 42 clusters (containment areas). A total of 22,693 individuals
of 30 clusters received Arsenicum album 30C and 9493
individuals of 12 clusters were observed in the control group.
The protective effect of the Arsenicum album 30C against
laboratory-confirmed COVID-19 was 68.22% (95% confidence
interval [CI]: 49.64–80; 32 cases/22,693 [4.83/10,000 personweeks] in the Arsenicum album 30C group vs. 42 cases/9493
[14.93/10,000 person-weeks] in the control group). Arsenicum
album 30C was associated with a decrease in the incidence
and provided protection against COVID-19 as compared to the
non-treatment group.

Role of Arsenic Album 30C in COVID-19 Cases
Title: Effectiveness of Arsenicum album 30C in the Prevention
of COVID-19 in Individuals Residing in Containment Zones of
Delhi – A Prospective, Community-based, Parallel Cohort Study
Authors: Debadatta Nayak, Karanpreet Nahar, Rupali
Bhalerao, Lovepreet Kaur, Tabassum Parveen Ruchika Bhalla,
James Michael, Swati Sharma, Parul Singh, Afsana Jainab,
Hanuman Ram, Abhishek Chaudhuri, Ummesalma Parvin,
Nidhi Jain, Anil Khurana
Journal: Homoeopathy. DOI: 10.1055/s-0042-1745755.
330

Summary: This was a prospective parallel cluster cohort study
conducted between April 2020 and August 2020 to evaluate
the effectiveness of Arsenicum album 30C on the incidence
of COVID-19 in individuals in containment areas of Delhi.
Participants were enrolled in two cohorts: The homoeopathy
intervention (HI) cohort and the non-intervention (NI) cohort.
A population of 10,392 was screened, and 10,180 (HI cohort,
n = 6,590; NI cohort, n = 3,590) participants were enrolled
from the community, where local transmission had been
reported and declared a containment zone by the local health
authority. A total of 212 individuals were excluded, as they
did not meet the inclusion criteria. The overall effectiveness of
Arsenicum album 30C was 83.43% (95% [CI], 76.77–88.17):
45 cases/6590 (8.34/10,000 person-weeks) in Arsenicum album
30C group vs. 143 cases/3590 (45.01/10,000 person-weeks) in
the NI cohort. The protective effect of Arsenicum album 30C
against laboratory-confirmed COVID-19 was 74.40% (95%
CI, 55.08–85.41): 18 cases/6590 (3.32/10,000 person-weeks) in
Arsenicum album 30C group vs. 38 cases/3590 (11.85/10,000
person-weeks) in the NI cohort.
Comments (For study no. 5, 6 and 7): During the first phase
of the pandemic where there were no known preventive
modalities, Arsenic album 30 was distributed as a mass
prophylaxis. Data analysis identifies a high protection
provided by the medicine. The homoeopathic genus
epidemicus based on symptomatology can be used in initial
phase of an epidemic till laboratory-based virological and
immunological studies can identify more specific protective
agents.

Effectiveness of Homoeopathic Medicines in the
Second Wave of COVID-19
Title: Homoeopathic Medicines in the Second Wave of
COVID-19: Prognostic Factor Research
Authors: Raj Kumar Manchanda , Anjali Miglani , Moumita
Chakraborty, Amrit Kalsi, Baljeet Singh Meena, Prabhjeet
Kaur, Beenu Saini, Amit Arora, Cheshta Nagrath, Jithesh
Thavarayil Kannoth, Ram Kumar Kudiyarasu, Rahul Vardaan,
Smita Brahmachari, Yogesh Kumar, B. Amitav, Pramod
Konthembath, Ankit Gupta, Suresh Kumar Lolugu, Pawan
Goel,Shelly Arora, Shirin Balan, Kavita Sharma, Anu Chawla,
Malaya Kumar Ray, Vineetha Susan Jacob, Udesh Kumar,
Vikas Kumar Verma, Rahul Kumar Singh, Abishes Saha,
Manjula Ghuliani, Paramjeet Kaur, Shruti Gora, Meeta Gupta,
Brender Sharma, Lex Rutten
Journal: Homoeopathy. DOI: 10.1055/s-0042-1748881
Summary: This was a retrospective, multicentred observational
study performed from March 2021 to May 2021 on confirmed
COVID-19 cases who were either in home isolation or at COVID
Care Centres in Delhi, India. The data were collected from
integrated COVID Care Centres where homoeopathic medicines
were prescribed along with conventional treatment. Out of 769
confirmed COVID-19 cases reported, 514 cases were selected for
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analysis, including 467 in home isolation. Of these, 70 patients
took only homoeopathic treatment while 444 used conventional
symptomatic treatment as well as homoeopathy. The most
common complaints were cough, fever, myalgia, sore throat,
loss of taste and/or smell and anxiety. Certain new symptoms
for example, headache, dryness of mouth and conjunctivitis,
were also seen. Thirty-nine medicines were prescribed, the most
frequent being Bryonia alba (161 cases) followed by Arsenicum
album (98 cases), Pulsatilla nigricans (51 cases), Belladonna
(31 cases), Gelsemium sempervirens (27 cases), Hepar sulphuris
(22 cases), phosphorus (17 cases), Rhus toxicodendron (14 cases)
and Mercurius solubilis (14 cases).
Comments: Results of this study show that homoeopathy
can offer support as an adjunct therapy, along with
conventional drugs, in clinical management of the
COVID-19 pandemic. It also confirms the prognostic factors
of four medicines used in the authors’ previous study.
Add-on use of homoeopathic medicines has also shown
encouraging results in the second wave of COVID-19 in
the integrated care facilities.
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